구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | CD19-CAR(Mem) T-cells |
Overview Company | St. Jude Children's Research Hospital |
Overview Modality | CGT |
Overview Target | CD19 |
Overview Indication | Acute Lymphoblastic Leukemia, in Relapse; Acute Lymphoblastic Leukemia, Refractory |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Genetics of Response to Canagliflozin (GRC) Study: Rationale, Design, and Pharmacodynamic Responses.. Sodium glucose cotransporter-2 (SGLT2) inhibitors are a class of antidiabetics with benefits including HbA1c-lowering, weight loss, cardiovascular and renal protection in addition to adverse effects including genitourinary tract infections, ketoacidosis, and bone loss. Here, we describe the ration… |
Toxicology CRS | Reported |
Clinical Safety signal | Genetics of Response to Canagliflozin (GRC) Study: Rationale, Design, and Pharmacodynamic Responses.. Sodium glucose cotransporter-2 (SGLT2) inhibitors are a class of antidiabetics with benefits including HbA1c-lowering, weight loss, cardiovascular and renal protection in addition to adverse effects including genitourinary tract infections, ketoacidosis, and bone loss. Here, we describe the ration… |
Clinical Selected reported efficacy | ORR 67% |
Clinical Reported ORR | 67% |
Clinical Result source | ClinicalTrials.gov NCT03704298 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT03704298 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | CD19-CAR(Mem) T-cells |
Overview Company | St. Jude Children's Research Hospital |
Overview Modality | CGT |
Overview Target | CD19 |
Overview Indication | Acute Lymphoblastic Leukemia, in Relapse; Acute Lymphoblastic Leukemia, Refractory |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Genetics of Response to Canagliflozin (GRC) Study: Rationale, Design, and Pharmacodynamic Responses.. Sodium glucose cotransporter-2 (SGLT2) inhibitors are a class of antidiabetics with benefits including HbA1c-lowering, weight loss, cardiovascular and renal protection in addition to adverse effects including genitourinary tract infections, ketoacidosis, and bone loss. Here, we describe the ration… |
Toxicology CRS | Reported |
Clinical Safety signal | Genetics of Response to Canagliflozin (GRC) Study: Rationale, Design, and Pharmacodynamic Responses.. Sodium glucose cotransporter-2 (SGLT2) inhibitors are a class of antidiabetics with benefits including HbA1c-lowering, weight loss, cardiovascular and renal protection in addition to adverse effects including genitourinary tract infections, ketoacidosis, and bone loss. Here, we describe the ration… |
Clinical Selected reported efficacy | ORR 67% |
Clinical Reported ORR | 67% |
Clinical Result source | ClinicalTrials.gov NCT03704298 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT03704298 |
추천 비교
추천 비교